Ann Punnoose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ann Punnoose has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anne I. Dipchand
Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, Ontario, Canada
1 shared publication - David N. Rosenthal
Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California
1 shared publication - Donna R. Rivera
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD
1 shared publication - Elizabeth Anne Greene
Professor of Pediatrics, University of New Mexico, Pediatric Cardiology Division, Director, Pediatric Electrophysiology and Exercise Testing, Albuquerque, New Mexico
1 shared publication - Jacqueline M. Smits
Eurotransplant International Foundation Leiden the Netherlands
1 shared publication - Jeffrey G. Gossett
Northwell Health, Cohen Children's Heart Center New Hyde Park New York USA
1 shared publication
Latest Publications
- 27 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (3) , 545-547
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
Advances in the availability and analysis of real‐world data (RWD) have enabled the generation of robust real‐world evidence (RWE) to support regulatory decision making by the US Food and Drug Administration. Realizing the full potential of RWE in a regulatory environment requires cross‐discipline expertise and collaboration to increase confidence in RWE‐based approaches. The FDA's Advancing RWE Program was established to address this need by providing a new option for regulatory interactions on RWE‐based approaches.
- 27 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (3) , 545-547
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
Advances in the availability and analysis of real‐world data (RWD) have enabled the generation of robust real‐world evidence (RWE) to support regulatory decision making by the US Food and Drug Administration. Realizing the full potential of RWE in a regulatory environment requires cross‐discipline expertise and collaboration to increase confidence in RWE‐based approaches. The FDA's Advancing RWE Program was established to address this need by providing a new option for regulatory interactions on RWE‐based approaches.
- 20 March 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (3) , e13665
Review of interactions between high‐risk pediatric heart transplant recipients and marginal donors including utilization of risk score models
Background: Donor organ acceptance practices vary among pediatric heart transplant professionals. We sought to understand what is known about the interactions between the “high‐risk” recipient and the “marginal donor,” and how donor risk scores can impact this discussion.Methods: A systematic review of published literature on pediatric HTx was undertaken with the assistance of a medical librarian. Two authors independently assessed search results, and papers were reviewed for inclusion.Results: We found that there are a large number of individual factors, and clusters of factors, that have been used to label individual recipients “high‐risk” and individual donors “marginal.” The terms “high‐risk recipient” and “marginal donor” have been used broadly in the literature making it virtually impossible to make comparisons between publications. In general, the data support that patients who could be easily agreed to be “sicker recipients” are at more risk compared to those who are clearly “healthier,” albeit still “sick enough” to need transplantation. Given this variability in the literature, we were unable to define how being a “high‐risk” recipient interplays with accepting a “marginal donor.” Existing risk scores are described, but none were felt to adequately predict outcomes from factors available at the time of offer acceptance.Conclusions: We could not determine what makes a donor “marginal,” a recipient “high‐risk,” or how these factors interplay within the specific recipient‐donor pair to determine outcomes. Until there are better risk scores predicting outcomes at the time of organ acceptance, programs should continue to evaluate each organ and recipient individually.
- 20 March 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (3) , e13665
Review of interactions between high‐risk pediatric heart transplant recipients and marginal donors including utilization of risk score models
Background: Donor organ acceptance practices vary among pediatric heart transplant professionals. We sought to understand what is known about the interactions between the “high‐risk” recipient and the “marginal donor,” and how donor risk scores can impact this discussion.Methods: A systematic review of published literature on pediatric HTx was undertaken with the assistance of a medical librarian. Two authors independently assessed search results, and papers were reviewed for inclusion.Results: We found that there are a large number of individual factors, and clusters of factors, that have been used to label individual recipients “high‐risk” and individual donors “marginal.” The terms “high‐risk recipient” and “marginal donor” have been used broadly in the literature making it virtually impossible to make comparisons between publications. In general, the data support that patients who could be easily agreed to be “sicker recipients” are at more risk compared to those who are clearly “healthier,” albeit still “sick enough” to need transplantation. Given this variability in the literature, we were unable to define how being a “high‐risk” recipient interplays with accepting a “marginal donor.” Existing risk scores are described, but none were felt to adequately predict outcomes from factors available at the time of offer acceptance.Conclusions: We could not determine what makes a donor “marginal,” a recipient “high‐risk,” or how these factors interplay within the specific recipient‐donor pair to determine outcomes. Until there are better risk scores predicting outcomes at the time of organ acceptance, programs should continue to evaluate each organ and recipient individually.
- 1 February 2016
- Published by American Academy of Pediatrics (AAP)
- Vol. 26 (3) , 507-527
Sports-Related Sudden Cardiac Injury or Death
*Corresponding author, E-mail address: EGreene@salud.unm.edu
- 1 February 2016
- Published by American Academy of Pediatrics (AAP)
- Vol. 26 (3) , 507-527
Sports-Related Sudden Cardiac Injury or Death
*Corresponding author, E-mail address: EGreene@salud.unm.edu